



MEDIA ADVISORY FOR IMMEDIATE RELEASE 05-21-13

Howard University College of Pharmacy signed a cooperation agreement with TNI BioTech Inc (TNIB OTC-QB), to assist in the development of TNI BioTech immunotherapy as part of their goal to provide affordable healthcare and development of pharmaceutical skills in Africa.

Washington, D.C. The relationship forged between TNI BioTech and Howard University College of Pharmacy, by TNI BioTech VP of African Affairs, Dr. Ndiouga Dieng and Dr. Gloria B. Herndon of GB Group Global & Chair of NAFEO Corporate Board, has strategically positioned both organizations strongly in the area of developing affordable immunotherapy, implementing best practices in cGMP manufacturing and fostering the development of pharmaceutical skills particularly in Africa.

Howard University College of Pharmacy has agreed to support the Product Development of new and commercial delivery of Low Dose Naltrexone (LDN); e.g., oral capsules/tablets & topical creams and development of commercial delivery form(s) for Met-Enkephalin (MENK). Furthermore, Howard University will provide assistance in clinical trials in multiple African countries for LDN and MENK for several disease indications such as HIV/AIDS, cancer, Crohn's, Multiple Sclerosis and other autoimmune diseases. Dr. Joseph Fortunak, Associate Professor, Chemistry and Pharmaceutical Sciences at Howard University, will be the lead on the project development including full regulatory approvals in the United States, China and multiple African countries.

Dr. Anthony Wutoh, Dean, Professor & Center Director at the Center for Minority Health Services and the Research Center of Excellence at Howard University College of Pharmacy stated that they "...are very excited about the opportunity to collaborate with TNI BioTech and to develop medications that may be effective in the treatment of HIV/AIDS, cancer and other disorders. We look forward to partnering and providing our expertise in drug manufacturing, conducting clinical trials and providing regulatory training for pharmaceutical development. We are especially pleased to provide support to assist nations in Africa, underscoring our commitment to the development of people in Africa and throughout the African Diaspora..."

TNI BioTech will also assist Howard University College of Pharmacy in locating funding for the upgrade of The Center for Drug Research and Development the facility. Once completed and qualified as a cGMP facility it will be able to provide manufacturing not only to TNI BioTech but others companies looking to manufacture in the United States for distribution both domestically and abroad. Furthermore, it will also provide a revenue stream to the College of Pharmacy that will expansion of its operations to students around the world.

Ms. Noreen Griffin, CEO of TNI BioTech mentioned that they "...are very pleased to enter this agreement with Howard University, as no University has the experience and commitment to Africa that Howard has and it is this very experience and expertise of its professors that will allow TNI BioTech to be able to implement both of our business and health care commitment to Africa. Howard today has health care projects in Nigeria, Zambia, Malawi, Ethiopia, Rwanda, Tanzania and South Africa, which will allow them to help us develop new protocols, obtain regulatory approvals and oversee our clinical trials. We believe that this agreement with Howard University enhances our relationship with the University and creates a

new model for important industry-academic drug development and corporation on an international scale. We have also come to understand that the partnership also aligns with Howard University College of Pharmacy's goals in shaping the future of pharmacy science and working collaboratively.

About TNI BioTech: *At TNI BioTech, Inc., our goal is to benefit patients with chronic and often life-threatening diseases through the activation and rebalancing of the body's immune system using our patented immunotherapy. Our products, technologies, and patents are designed to harness the power of the immune system to improve the treatment of cancer and infections, such as HIV/AIDS and autoimmune diseases. We are currently developing active and adoptive forms of immunotherapies. Our most advanced clinical programs involve immunotherapy with Met-Enkephalin (MENK) or low dose naltrexone, which both work by triggering opioid receptors on immune cells and lead to an activation and expansion of various cells in the immune system.*

About Howard University College of Pharmacy: *Consistent with the mission of Howard University, the College of Pharmacy mission aims to provide pharmaceutical education of excellent quality to students with high academic, scholarship and leadership potential, with particular emphasis upon the recruitment, retention and graduation of promising African-American and other ethnically diverse minority students. The primary goals of the College of Pharmacy are: 1.) To recruit, train and educate qualified African-American and other ethnically diverse minority students to assume leadership roles in pharmacy 2.) To produce skilled pharmaceutical care practitioners, proficient pharmaceutical scientists and competent educators to meet the challenges of the profession and society 3.) To recruit and retain a cadre of faculty dedicated to teach and mentor students, conduct research and pursue other scholarly activities that contribute to the growth and development of basic and clinical pharmaceutical sciences 4.) To provide postgraduate and continuing professional education and community services that will enhance the quality of pharmaceutical care.*

About LDN: *Naltrexone is an FDA-approved product for alcohol or opiate dependence; prescriptions are currently being filled for 50mg naltrexone by hundreds of local and mail-order pharmacies around the US. TNIBioTech intends to use the FDA 505(b) (2) pathway to study and gain approval by the FDA for its own trademark LDN in other diseases, with Crohn's disease as its first therapeutic indication. LDN treatment appears to modulate the immune system so that it decreases the inflammatory attack on normal cells of the body and allows an improvement in normal functions of the nerves or gastrointestinal cells. As a result, treatment with LDN is potentially synergistic in combination with current drugs for autoimmune diseases such as multiple sclerosis (MS) and Crohn's disease. As naltrexone is widely available for off-label use at low-cost, both in and outside the US, TNIB's near-term strategy focuses on making the company's treatments available in countries where the urgent need exists for readily available safe and effective treatments for autoimmune diseases, AIDS and cancer patients. TNIB's goal is to establish facilities to distribute these immunotherapy products in many countries in Africa, Caribbean and South America.*

About MENK: *TNIB's MENK-based immunotherapies enhance the immune system response by increasing production and activation of dendritic cells, macrophages, CD4+ T Cells (CD4), CD8+ T cells, NK cells, NKT cell and gamma/delta T cells and inhibiting T regulatory cells to allow the body to recognize cancer cells as foreign invaders and thereby remove these cancer cells. Treatment with MENK has potential clinical efficacy while avoiding certain deleterious effects on the body, as is often the case with traditional chemotherapy. The costs are reasonable, making this an attractive complement for a large number of cancer patients.*

MEDIA CONTACT:

Jan Du Plain

jan@duplain.com

202-486-7004